statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Codexis, Inc. (NASDAQ:CDXS - Get Free Report) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 2,290,000 shares, a decrease of...

Codexis, Inc. (NASDAQ:CDXS) Sees Significant Decrease in Short Interest

Shares of Codexis, Inc. (NASDAQ:CDXS  Get Free Report) have earned a consensus rating of Moderate Buy from the six brokerages that are currently covering the firm...

Brokerages Set Codexis, Inc. (NASDAQ:CDXS) PT at $6.80

Investors eyeing a purchase of Codexis Inc (CDXS) stock, but tentative about paying the going market price of 3.51/share, might benefit from considering selling puts among the alternative...

Commit To Buy Codexis At $2.50, Earn 20.1% Annualized Using Options

SG Americas Securities LLC raised its holdings in shares of Codexis, Inc. (NASDAQ:CDXS  Free Report) by 19.1% during the 4th quarter, according to the company in its most recent 13F filing...

Codexis, Inc. (NASDAQ:CDXS) Stake Increased by SG Americas Securities LLC

This is a Bearish indicator signaling CDXS's price could decline from here. Traders may explore shorting the stock or put options...

Codexis (CDXS, $3.47) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 8, 2024

Shares of Codexis, Inc. (NASDAQ:CDXS  Get Free Report) have received a consensus rating of Moderate Buy from the six research firms that are presently covering the firm...

Codexis (NASDAQ:CDXS  Get Free Report) was upgraded by research analysts at StockNews.com to a sell rating in a research note issued on Tuesday.
CDXS has been the topic of a...

Codexis (NASDAQ:CDXS) Rating Increased to Sell at StockNews.com

This is a signal that CDXS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Codexis (CDXS, $4.21) RSI Indicator left the overbought zone on March 04, 2024

Codexis, Inc. (NASDAQ:CDXS  Get Free Report) has received a consensus recommendation of Moderate Buy from the six research firms that are presently covering the firm, Marketbeat...

Codexis, Inc. (NASDAQ:CDXS) Receives $6.80 Average Price Target from Analysts

Benchmark upgraded shares of Codexis (NASDAQ:CDXS  Free Report) from a hold rating to a buy rating in a report published on Thursday, MarketBeat reports. They currently have $9.00 target price...

Benchmark Upgrades Codexis (NASDAQ:CDXS) to Buy

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Volume	204,345.00
52-Wk High	$4.91
52-Wk Low	$1.45

CDXS Codexis Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals